DGAT2 and type 2 diabetes mellitus: The present study hypothesizes that TDQ, acting as a PPARγ agonist and a DGAT2 inhibitor, not only alleviate glucose and lipid metabolism disorder but also ameliorate IR in type 2 diabetic rats.